ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Catalent will spend $200 million in a three-year program to expand drug-substance manufacturing and fill-and-finish capacity at its Madison, Wisconsin, and Bloomington, Indiana, biologics plants. Mammalian cell culture capacity will increase in Madison with the addition of two new suites, each with a pair of 2,000 L single-use bioreactors. Work should be complete by 2021, more than doubling the current capacity. The Bloomington site will see a new high-speed vial line that operates at a filling speed of 300 units/min.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X